Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.
This book provides up-to-date guidance on the use of FDG PET to assess the biological activity and treatment response of a wide range of malignancies, including, for example, lung cancer, breast cancer, head and neck cancer, gastrointestinal cancer, and malignant lymphoma.
Hirofumi Fujii、M.D., Ph.D. Division of Functional ImagingExploratory Oncology Research and Clinical Trial CenterNational Cancer CenterKashiwa, JapanProfessor Hiroyuki Nakamura, M.D., Ph.D.Department of Respiratory MedicineTokyo Medical University Ibaraki Medical CenterIbaraki, Japan Seiei Yasuda, M.D., Ph.D.Chairman of the board of trusteeYotsuya Medical CubeTokyo, Japan
1Overview.-2Lung cancer.-3Breast cancer.- 4Head and neck cancer.-5Gastrointestinal cancer including GIST.- 6Pancreatic cancer.- 7Urological cancer.- 8Malignant bone and soft tissue tumors.- 9 Skin cancer including malignant melanoma.- 10Malignant lymphoma.
“The book provides a detailed and insightful perspective … . It would make an interesting read for the inquisitive PETCT scholar, and it would be an invaluable tool for the reader who is interested in comparing PETCT practices across various jurisdictions.” (Wai Lup Wong, RAD Magazine, January, 2023)